Skip to main content
Clinical Trials/NCT03330470
NCT03330470
Completed
Not Applicable

Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease

Slovak Academy of Sciences3 sites in 2 countries26 target enrollmentJanuary 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Subjective Cognitive Impairment
Sponsor
Slovak Academy of Sciences
Enrollment
26
Locations
3
Primary Endpoint
glucose tolerance
Status
Completed
Last Updated
11 months ago

Overview

Brief Summary

The purpose of this study is to investigate the beneficial effects of regular exercise and the impact of food supplement carnosine on cognitive, motoric and metabolic functions as well as on specific biologically active substances in volunteers with subjective (SCI) or mild (MCI) cognitive impairment, as well as in patients in early stages of Parkinson's disease. The investigators assume the immediate intervention-associated health benefit for volunteers.

Detailed Description

Standard Operating Procedures for patient recruitment, data collection, data management, data analysis routinely used in Biomedical Research Center, Slovak Academy of Sciences, University Hospital Bratislava and Comenius University, Bratislava will be employed. Gait and balance parameters will be examined and analysed at the Department of Behavioural Neuroscience, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia Statistical analysis will be employed to address the primary and secondary objectives, as specified in the study protocol.

Registry
clinicaltrials.gov
Start Date
January 1, 2017
End Date
September 30, 2023
Last Updated
11 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Barbara Ukropcová, MD, PhD

Prof. MD, PhD

Slovak Academy of Sciences

Eligibility Criteria

Inclusion Criteria

  • Signed informed consent
  • Age 55 - 80 years
  • Presence of Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment (MCI) or early stage of Parkinson's Disease (Hoehn-Yahr 1st-2nd stage), assessed by experienced neurologist

Exclusion Criteria

  • Serious systemic cardiovascular, hepatic, renal disease, cancer
  • Lack of compliance

Outcomes

Primary Outcomes

glucose tolerance

Time Frame: up to 36 months

changes in glucose tolerance will be determined with oral glucose tolerance test (2h glucose, mmol/l)

learning/working memory

Time Frame: up to 36 months

exercise related changes in learning/working memory will be determined with the aid of Addenbrook's cognitive test (maximum test score 100)

Balance parameter (Berg Balance Scale)

Time Frame: up to 36 months

Exercise related changes in ballance will be examined with the Berg Balance Scale test (max score 56)

Secondary Outcomes

  • habitual physical activity(up to 36 months)
  • physical fitness(up to 36 months)
  • Gait parameters (Walking speed)(24 months)
  • Gait parameter (Stance time)(24 months)
  • Gait parameter (step length)(24 months)
  • Postural parameter (magnitude of CoP displacement)(24 months)
  • Postural parameter (Velocity CoP displacement)(24 months)
  • Postural Sway Area(24 months)
  • Postural sway path length(24 months)
  • Postural sway frequency(24 months)
  • Acceleration of upper and lower trunk(24 months)
  • Upper and lower trunk sway area(24 months)
  • Upper and lower trunk sway path(24 months)
  • Upper and lower trunk sway frequency(24 months)
  • Upper and lower trunk sway jerkiness(24 months)
  • Angular velocity of upper and lower trunk(24 months)

Study Sites (3)

Loading locations...

Similar Trials